The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4/6 inhibitor resistance
Article in Cancer Research (September 2023)
The most recent citing publications are shown below. View all 50 publications that cite this research output on Dimensions.
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
Article in npj Breast Cancer (August 2023)
Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges
Article in Journal of Medicinal Chemistry (June 2023)